Clarithromycin/Rabeprazole Sodium/Amoxicillin

克拉霉素/雷贝拉唑钠/阿莫西林

Report date: 2026/03/04 20:01:44

Base Information

Drug NameClarithromycin/Rabeprazole Sodium/Amoxicillin

Drug Alias Name阿莫西林/克拉霉素/雷贝拉唑钠Amoxycillin Trihydrate/Clarithromycin/Rabeprazole Sodium阿莫西林/雷贝拉唑钠/克拉霉素Rabeprazole Sodium/Clarithromycin/Amoxicillin Hydrate雷贝拉唑钠/克拉霉素/阿莫西林水合物 +[6]

ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibioticsSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics

Mechanisms of Action50S ribosomal subunit inhibitorsProton pump inhibitorsBacterial penicillin-binding protein inhibitors

Targets50S ribosomal subunitProton pumpBacterial penicillin-binding protein

Therapy Area/IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[6]

Global Approved IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[6]

Approved Indications in ChinaN/A

Original Approved Country/TerritoryJapan

Original Approved Date2013/08/15

Country/TerritoryJapan

CombinationsYes Clarithromycin Rabeprazole Sodium Amoxicillin

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesEisai Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesEisai Co Ltd

Inactive CompaniesN/A

Active IndicationsHelicobacter pylori infectionPurpura, Thrombocytopenic, IdiopathicStomach Ulcer +[6]

Inactive IndicationsN/A

Other Information

ATC CodeA02BD12